Search

Search Results

• Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

  Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  12-11-2024

  https://doi.org/10.4081/dr.2024.10080

  1222

  PDF: 689

  HTML: 31

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1776

  PDF: 687

  HTML: 99
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1070

  PDF: 550

  HTML: 24
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1949

  PDF: 735

  HTML: 31

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1012

  PDF: 534

  SUPPLEMENTARY MATERIAL: 159

  HTML: 18
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1374

  PDF: 754

  HTML: 12

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  435

  PDF: 303

  HTML: 1
• 

  Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

  Trang Thi Thuy Le, Thang Tat Nguyen, Chuyen Thi Hong Nguyen, Hao Trong Nguyen, Trung The Van

  27-10-2021

  https://doi.org/10.4081/dr.2021.9398

  3128

  PDF: 584

  HTML: 13

• Hidradenitis suppurativa: state-of-the-art review and update

  Marco Virone, Elena Zappia, Alberto Di Caro, Davide Carlesimo, Nicoletta Bernardini, Giovanni Pellacani, Antonio Giovanni Richetta, Steven Paul Nisticò, Annunziata Dattola

  27-08-2025

  https://doi.org/10.4081/dr.2025.10328

  789

  PDF: 592

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  806

  PDF: 464

  HTML: 20

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  434

  PDF: 287

  HTML: 14

• Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female

  Caterina Mariarosaria Giorgio, Anna Balato, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Eugenia Veronica Di Brizzi

  21-02-2025

  https://doi.org/10.4081/dr.2025.10278

  462

  PDF: 302

  HTML: 16
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1172

  PDF: 830

  HTML: 44